|
|
Article: Pathogenesis Corp. Begins Patient Enrollment in TOBI Clinical Trial in The United Kingdom and Ireland.
- Article from:
- PR Newswire
- Article date:
- April 15, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, April 15 /PRNewswire/ -- PathoGenesis Ltd., a subsidiary of PathoGenesis Corp. (Nasdaq: PGNS), has begun to enroll patients in an open-label, randomized clinical trial of TOBI(R) (tobramycin solution for inhalation) at 14 cystic fibrosis centers in the United Kingdom and Ireland. While the study is not required for regulatory approval of TOBI in Europe, it will give European clinicians hands-on experience with the drug, which is currently approved for sale in the U.S., Canada and Argentina.
PathoGenesis plans to enroll 120 patients age six and older who have been diagnosed with cystic fibrosis and Pseudomonas aeruginosa lung infections. The 28-day trial ...